About Dale Pfost
Dale Pfost is a director of 28bio, Inc. AxoSim, Inc. announced on February 28, 2024 that he and David Weiner became co-chairs of its board. AxoSim develops and applies 3D organoid neurodiscovery platforms. Pfost has a doctorate in physics from Brown University and a bachelor's degree from the University of California, Santa Barbara.
Pfost has served as chief executive officer of six biotechnology companies. Three of them became publicly traded. He became chief executive officer of Chemomab Therapeutics on October 25, 2021, and had retired from the role by February 2024. Before that, he led Lodo Therapeutics as chief executive officer until its acquisition. He was founding chief executive officer of Acuity Pharmaceuticals, Oxford GlycoSciences and Orchid BioSciences. He also led Receptor BioLogix to an acquisition as chief executive officer. He was a general partner at Advent Life Sciences, a venture capital firm. He was acting chief executive officer of MicroBiome Therapeutics, which he co-founded.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Dale Pfost in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Dale Pfost works with at each company, as listed on that company's latest Form D.
